Indivior Pharmaceuticals, Inc 6-K, filed Nov 9, 2023
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2023-11-09
For: 2023-11-09
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on November 9, 2023.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: November 9, 2023
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Description of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: November 9,
2023
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
Indivior PLC - Appointment of Independent
Non-Executive Director
Slough, UK and Richmond, VA, November 9, 2023 - Indivior PLC (LSE/NASDAQ:
INDV) announces the appointment of Keith Humphreys, OBE, PhD,
as an Independent Non-Executive Director of the Company with
immediate effect. Dr. Humphreys has also been appointed as a
member of the Compliance, Ethics & Sustainability, Nomination
and Science Committees.
Dr. Humphreys is an Esther Ting Memorial Professor in the
Department of Psychiatry and Behavioral Sciences at Stanford
University. He was previously a Senior Policy Advisor in the
White House Office of National Drug Control Policy in the Obama
Administration and is an Honorary Professor of Psychiatry at the
Institute of Psychiatry, King's College, London. Dr.
Humphreys was awarded an OBE in September 2022 for his services to
science and policy on addiction.
Dr. Tom McLellan will continue to serve as a Non-Executive Director
to support a smooth transition and will step down from the Board
with effect from February 29, 2024.
Graham Hetherington, Chair, commented:
'We are pleased to have Keith join Indivior's Board as an
Independent Non-Executive Director. With over 30 years of
experience in the field of clinical psychology and substance use
disorders, Dr. Humphreys is one of the leading minds in the
substance abuse space and his research addresses addictive
disorders and translation of science into public policy. He will be
a tremendous asset as we continue to focus on our purpose of
bringing science-based, life-transforming treatments to
patients.'
'On behalf of the Board, I would like to take this opportunity to
thank Tom for his significant contribution and commitment to
Indivior over the last nine years, and appreciate his dedication to
the furtherance of our and the public's understanding of the
substance use disorder disease space.'
There is no further information to disclose in relation
to Keith Humphreys' appointment in accordance with
Listing Rule 9.6.13.
This announcement is made in accordance with Listing Rule
9.6.11.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat addiction and
serious mental illnesses. Our vision is that all patients around
the world will have access to evidence-based treatment for the
chronic conditions and co-occurring disorders of substance use
disorder (SUD). Indivior is dedicated to transforming SUD from a
global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and co-occurring disorders of SUD, including alcohol use
disorder and cannabis use disorder. Headquartered in the
United States in Richmond, VA, Indivior employs more
than 1,000 individuals globally and its portfolio of products is
available in 37 countries worldwide.
Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.